

Metabolic Continuum Roundtable™

A Forum for Collaborative Science & Translational Clinical Research

Leading hepatologists, endocrinologists and clinical development experts addressing challenges in drug development for metabolic continuum diseases

The Metabolic Continuum Roundtable™ was established in 2018 as a platform to stimulate collaboration and dialogue and to support the development of effective and safe treatments for steatotic liver disease. Its contributors are distinguished scientific and clinical development experts brought together by their common commitment to steward advances in science, clinical research and therapeutics for metabolic continuum diseases.

The Metabolic Continuum Roundtable meets twice yearly and is a forum to support the development of effective and safe treatments and build consensus towards validated biomarkers and clinical trial endpoints.

The Metabolic Continuum Roundtable contributors represent cross-functional expertise in metabolic research, drug development, and patient care, and hail from prominent academic and medical centers in North America, Europe, and Asia. Brought together by their common commitment to steward advances in science, clinical research, and therapeutics, their collaborative efforts aim to improve patient outcomes and propel advancements in knowledge within the global scientific community.

The Roundtable is accessible to biopharma to consult on:

- Metabolic disease treatment development programs
- Clinical development and regulatory planning
- Clinical and pre-clinical study design
- Biomarker strategies
- Applicable & relevant clinical research methods
- Asset evaluation and risk assessment
- Competitive and scientific landscape review

Distinguished Metabolic Continuum Roundtable Contributors

Elisabetta Bugianesi MD, PhD

Professor of Gastroenterology, School Medicine at the University of Torino, Italy

Kenneth Cusi, MD

Professor and Chief, Division of Endocrinology, Diabetes and Metabolism at University of Florida

Joel E. Lavine, MD, PhD

Professor of Pediatrics and Chief of Pediatric Gastroenterology, Hepatology and Nutrition at Columbia College of Physicians and Surgeons

Rohit Loomba, MD

Professor of Medicine, Director of Hepatology, at University of California at San Diego and Founding Director of the UCSD NAFLD Research Center

Vlad Ratziu, MD, PhD

Professor of Hepatology at Sorbonne Université and Pitié-Salpêtrière Hospital

Mary Rinella, MD

Professor of Medicine at Feinberg School of Medicine, Northwestern University

Michael Roden, MD

Director of the Deutsches Diabetes Zentrum and the Division of Endocrinology and Diabetology at Düsseldorf University Hospital

Manuel Romero-Gómez, MD

Professor of Medicine at University of Seville, Director of Digestive, Liver and Inflammatory Diseases Program at Institute of Biomedicine of Seville and UCM Digestive Diseases at Virgen del Rocío University Hospital

Arun J. Sanyal, MD, FAASLD

Z. Reno Vlahcevic Professor of Medicine at Virginia Commonwealth University School of Medicine

Detlef Schuppan, MD, PhD

Professor of Medicine, Hepatology and Gastroenterology, at Mainz University Medical Center and Beth Israel Deaconess Medical Center at Harvard Medical School

Miriam Vos, MD, MSPH

Associate Professor, Pediatrics and Division of Gastroenterology, Hepatology and Nutrition, at Emory University School of Medicine and Director, Pediatric Fatty Liver Program at Children's Healthcare of Atlanta

Vincent Wong, MD

Professor, Head of Division of Gastroenterology and Hepatology at the Chinese University of Hong Kong and Director of Cheng Suen Man Shook Centre for Hepatitis Research

Zobair Younossi, MD, MPH

Chairman and Professor of Medicine at Inova Fairfax Medical Campus

For more information about the Metabolic Continuum Roundtable, contact roundtable@prosciento.com or visit www.metabolic-continuum-roundtable.com

prosciento®
ADVISE • ADVANCE • ACHIEVE

Printed January 2024



Metabolic Continuum Roundtable™


A Forum for Collaborative Science & Translational Clinical Research

Leading hepatologists, endocrinologists and clinical development experts addressing challenges in drug development for metabolic continuum diseases

The Metabolic Continuum Roundtable™ was established in 2018 as a platform to stimulate collaboration and dialogue and to support the development of effective and safe treatments for steatotic liver disease. Its contributors are distinguished scientific and clinical development experts brought together by their common commitment to steward advances in science, clinical research and therapeutics for metabolic continuum diseases.

The Metabolic Continuum Roundtable meets twice yearly and is a forum to support the development of effective and safe treatments and build consensus towards validated biomarkers and clinical trial endpoints.

The Metabolic Continuum Roundtable contributors represent cross-functional expertise in metabolic research, drug development, and patient care, and hail from prominent academic and medical centers in North America, Europe, and Asia. Brought together by their common commitment to steward advances in science, clinical research, and therapeutics, their collaborative efforts aim to improve patient outcomes and propel advancements in knowledge within the global scientific community.



The Roundtable is accessible to biopharma to consult on:

- Metabolic disease treatment development programs
- Clinical development and regulatory planning
- Clinical and pre-clinical study design
- Biomarker strategies
- Applicable & relevant clinical research methods
- Asset evaluation and risk assessment
- Competitive and scientific landscape review

For more information about the Metabolic Continuum Roundtable, contact roundtable@prosciento.com or visit www.metabolic-continuum-roundtable.com

prosciento®
ADVISE • ADVANCE • ACHIEVE

Printed January 2024